Furthermore, paeoniflorin, albiflorin, baicalin, isoliquiritin, and liquiritin were reported to be active against depression and Parkinson's disease in in vivo studies and clinical trials, and paeoniflorin, baicalin and liquiritin were reported to inhibit NF-κB in vitro and in vivo. Here, NFKB1 is linked to depressive symptom measurement.